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VARIASI YANG DIPILIH PADA GEN ORGANIK ANION TRANSPORTING 
POLIPEPTIDA 2 (OATP2) DI KALANGAN NEONAT MELAYU YANG 
MENGALAMI DAN TIDAK MENGALAMI HIPERBILIRUBINEMIA 
 
ABSTRAK 
Hiperbilirubinemia neonatal adalah disebabkan oleh pelbagai faktor risiko 
termasuklah faktor genetik. Protein OATP2 yang dikodkan oleh gen OATP2 
memainkan peranan yang penting untuk membawa bilirubin dalam darah ke dalam 
sel hati. Terdapat pelbagai variasi genetik telah dilaporkan dan setiap daripadanya 
mempunyai frekuensi yang berbeza untuk setiap populasi. Fungsi variasi genetik 
yang terdapat pada gen OATP2 terhadap pembentukan hiperbilirubinemia neonatal 
masih kontroversi dan terdapat kekurangan kajian mengenai perkaitan antara 
kehadiran variasi genetik ini terhadap pembentukan hiperbilirubinemia neonatal 
termasuklah di kalangan orang Melayu di Malaysia. Pemilihan analisis untuk 
penyaringan variasi genetik juga adalah sangat penting untuk memastikan keputusan 
yang tepat dapat diperolehi. Objektif kajian ini adalah untuk mengenalpasti 
kehadiran variasi genetik yang telah dipilih dengan menggunakan analisis lebur 
resolusi tinggi (HRM), menentukan frekuensi genotip, alel dan haplotip di antara 
kumpulan yang mengalami dan tidak mengalami hiperbilirubinemia serta 
menentukan sama ada genotip dan haplotip memainkan peranan dalam pembentukan 
hiperbilirubinemia neonatal. Sampel sel pipi daripada 264 neonat telah diperoleh dan 
DNA diekstrak dengan menggunakan kit komersial pengekstrakan DNA. Analisis 
HRM digunakan untuk penyaringan variasi genetik dan sampel yang mempunyai 
bentuk graf yang berbeza akan dipastikan melalui analisis penjujukan DNA. 
xvi 
 
Daripada 14 variasi genetik yang telah dipilih, 9 variasi wujud dalam sampel neonat 
Melayu dan c.388 A>G merupakan variasi genetik yang mempunyai frekuensi yang 
tertinggi. Kajian ini juga menunjukkan bahawa kehadiran variasi genetik pada gen 
OATP2 tidak mempunyai perkaitan yang signifikan dengan pembentukan 
hiperbilirubinemia neonatal di kalangan neonat Melayu kecuali untuk genotip mutan 
heterozigot c.597 C>T yang menunjukkan frekuensi yang tinggi dalam kumpulan 
yang tidak mengalami hiperbilirubinemia. Analisis perkaitan antara tahap bilirubin 
serum dan genotip mendapati terdapat hubungan yang signifikan antara g.-11187 
G>A dan tahap bilirubin serum. Walaubagaimanapun, analisis perkaitan antara tahap 
bilirubin serum dan haplotip variasi genetik yang lain tidak menunjukkan perbezaan 
yang signifikan. Oleh itu, kajian lanjut perlu dilakukan untuk pengesahan.  
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SELECTED VARIATIONS OF THE ORGANIC ANION TRANSPORTING 
POLYPEPTIDE 2 (OATP2) GENE IN MALAY NEONATES WITH AND 
WITHOUT HYPERBILIRUBINAEMIA  
 
ABSTRACT 
Neonatal hyperbilirubinaemia is caused by many possible risk factors, 
including genetic factor. The OATP2 protein, which is encoded by OATP2 gene 
plays a crucial role in transporting bilirubin from the circulation to the hepatocytes. 
There are several genetic variations that have been reported and each of them was 
presence at different frequencies between population to population. The role of 
genetic variations of the OATP2 gene in the development of neonatal 
hyperbilirubinaemia is still controversial and there is lack of study investigated the 
association between the presence of genetic variations and neonatal 
hyperbilirubinaemia including in Malay population in Malaysia. The appropriate 
choice of screening method is also important to allow robust and accurate genotyping 
results. The objectives of this study is to screen for the selected genetic variations of 
the OATP2 gene using high resolution melting (HRM) analysis, to determine the 
genotype, allele as well as haplotype frequencies between hyperbilirubinaemia and 
non-hyperbilirubinaemia groups and to determine the association between genotypes 
and haplotypes with the development of neonatal hyperbilirubinaemia. Buccal cells 
sample of 264 neonates were collected and DNA was extracted using 
commercialized DNA extraction kit. HRM analysis was performed to screen for the 
selected genetic variations and samples that have different pattern of melt curve were 
confirmed by DNA sequencing analysis. Out of 14 genetic variations that were 
selected, 9 were presence in Malay neonates with the most common is c.388 A>G. 
xviii 
 
This study also shows that there was no significant association between genetic 
variations of the OATP2 gene with neonatal hyperbilirubinaemia in Malay neonates 
except for heterozygous mutant genotype of c.597 C>T that shows high frequency in 
non-hyperbilirubinaemia group. The analysis on the association between serum 
bilirubin levels and genotypes found there was a significant association of g.-11187 
G>A with serum bilirubin levels. However, the analysis on the association between 
serum bilirubin levels and haplotypes of other genetic variations shows no significant 
differences. Thus, further study need to be conducted for confirmation.  
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CHAPTER 1 
INTRODUCTION 
1.1 Research background  
Neonatal hyperbilirubinaemia or neonatal jaundice is common clinical 
condition among neonates (Akaba et al., 1999; Porter and Dennis, 2002). Severe 
hyperbilirubinaemia may lead to long-term effects including bilirubin 
encephalopathy and kernicterus and these cases become one of the serious 
problems in most of the developing countries. It caused mortality and long-term 
morbidity, about 10% and 70%, respectively (Blackmon et al., 2004; Ip et al., 
2004).  
The first primary factors that had been recognized to be associated with 
neonatal hyperbilirubinaemia including blood group and rhesus (Rh) 
incompatibilities, cephalohaematoma, breast feeding, weight loss, premature 
birth, polycythaemia, infants of diabetic mothers, glucose-6-phosphate 
dehydrogenase (G6PD) deficiency and ethnicity (Joseph et al., 1998; Newman 
and Maisels, 2000; Dennery et al., 2001; Harris et al., 2001; Huang et al., 2004). 
In addition, there were studies showed that neonatal hyperbilirubinaemia is 
common in male neonates as compared to female (Gale et al., 1990; A.A.o.P., 
2004; Ip et al., 2004).  
Even though these factors were identified to be related to the occurrence 
of severe hyperbilirubinaemia, however, it only contributes to 50% of neonates 
with non-physiological hyperbilirubinaemia (Büyükkale et al., 2011). Therefore, 
genetics is considered as one of the possible contributing factor and the 
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importance of genetic factors in development of neonatal hyperbilirubinaemia 
has been given great attention and it was recognized in many studies (Kaplan et 
al., 2002; Huang et al., 2004; Huang et al., 2005; Watchko, 2005). However, its 
functional role in the development of neonatal hyperbilirubinaemia remains 
unclear and seek for further investigation (Watchko et al., 2009). 
Many genes have been identified that involves in the aetiology of 
neonatal hyperbilirubinaemia. These genes including uridine diphosphate 
glucuronosyltransferase 1A1 (UGT1A1) (Laforgia et al., 2002; Long et al., 
2011), glutathione S-transferase (GST) (Muslu et al., 2008), glucose-6-phosphate 
dehydrogenase (G6PD) (Valaes, 1994; Johnson et al., 2002), organic anion 
transporting polypeptide 2 (OATP2) (Cui et al., 2001; Huang et al., 2004; 
Johnson et al., 2009; Lin et al., 2009; Bielinski et al., 2011; Liu et al., 2013), 
heme oxygenase-1 (HO-1) (Bozkaya et al., 2010), constitutive androstane 
receptor (CAR) (Huang et al., 2003) and multidrug resistance-associated protein 
2 (MRP2) (Lee et al., 2006). However, the frequencies and the contribution of 
each genetic variation in these genes were different between one population to 
one population across the world.  
As an example, c.388 A>G variation which is located in exon 4 of the 
OATP2 gene is common in Taiwanese neonates and proven to be a risk factor of 
developing severe neonatal hyperbilirubinaemia (Huang et al., 2004). In contrast, 
study by Watchko et al. (2009), shown that there was no association between 
c.388 A>G variation and neonatal hyperbilirubinaemia. Other than Taiwanese, 
this variation also been reported to be more common among African-American, 
Caucasian, Chinese and Malay population (Tirona et al., 2001; Mwinyi et al., 
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2004; Xu et al., 2007; Wong et al., 2012). Besides that, c.571 T>C variation is 
more common in Finnish population (Pasanen et al., 2006). This indicates that 
there is a significant difference of genetic variations among different population 
and the frequencies of each genetic variation is known to be race dependent.  
The OATP2 protein play an important role in the uptake of the bilirubin 
and its conjugates from the blood to the hepatocytes (Cui et al., 2001). Therefore, 
it is plausible that the presence of genetic variations in this gene may influence 
the transport activity of this protein and increase the susceptibility of the neonates 
to neonatal hyperbilirubinaemia. In addition, the impact the each genetic 
variation to the development of neonatal hyperbilirubinaemia is remained 
uncertain. 
Few studies about the association between genetic variations of the 
OATP2 gene with neonatal hyperbilirubinaemia among the Malaysian population 
including Malay, Chinese and Indian have been reported (Wong et al., 2009; 
Wong et al., 2012). Therefore, this study was carried out to further investigate the 
contribution of the genetic variations of the OATP2 gene to the development of 
neonatal hyperbilirubinaemia among Malay population.  
Other than calculating genotype and allele frequencies for each genetic 
variation, genetic linkage study was also conducted. In a genetic study, genetic 
linkage is a powerful method to determine the association between each genetic 
variation that lies in the same chromosome. Besides that, haplotype analysis was 
also included in order to determine the association between haplotypes and 
neonatal hyperbilirubinaemia. Many researchers have suggested that haplotype 
analysis is more powerful and useful method to analyse genetic variations and 
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their association with the disease as compared to traditional genotype-phenotype 
method (Niemi et al., 2004; Crawford and Nickerson, 2005; Jada et al., 2007).  
In order to screen for the genetic variations, high resolution melting 
(HRM) analysis was used and this method is a new technology, rapid and 
powerful method and able to screen the genetic variations in many clinically 
significant genes. According to the previous studies, HRM is a useful method to 
detect single nucleotide polymorphisms (SNPs), insertion and deletion (Krypuy 
et al., 2006; Bastien et al., 2008; Millat et al., 2009; Temesvári et al., 2011; 
Wong et al., 2012).  
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1.2 Rationale of the study  
Neonatal hyperbilirubinaemia is known to cause many prolonged adverse 
effects in term of health, medical cost and emotional burden to neonates’ parents. 
In term of health, neonatal hyperbilirubinaemia can cause severe brain damage if 
it is untreated. Even though there is standard treatment available such as 
phototherapy, exchange transfusion and pharmacological therapies, however, 
each of these methods may cause side effects to the neonates such as 
dehydration, infection and even death. Besides that, neonates with severe 
neonatal hyperbilirubinaemia may require a longer stay in hospital. Thus, it may 
cause an economic and emotional burden to the parents especially to whom that 
stay further from the hospital or come from the poor socioeconomic family.  
Thus, genetic study related to neonatal hyperbilirubinaemia need to be 
conducted. From the study, earlier occurrence of neonatal hyperbilirubinaemia 
can be predicted if the neonates carried certain genetic variations. It will help the 
doctors to give an early and better treatment before neonatal hyperbilirubinaemia 
getting more severe. Other than that, genetic study is closely related to the 
development of personalized medicine. Getting full information about the genes 
and genetic variations that lead to neonatal hyperbilirubinaemia may allow us to 
give customized medicines and specialized for each of the population. In 
addition, a new therapy strategy for prevention and treatment of neonatal 
hyperbilirubinaemia can be done after all data regarding related genetic 
variations were collected. 
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Thus, by having an effective medicine and treatment, the requirement for 
phototherapy and exchange transfusion can be reduced. The cost for hospital bills 
and the side effects from the treatments may also lessen. Other than that, this 
study may also leads to a better understanding of genetic factors related to 
neonatal hyperbilirubinaemia and lead to the improvement of scientific 
knowledge regarding neonatal hyperbilirubinaemia. 
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1.3 Objectives 
1.3.1 General objective 
To study the selected genetic variations of the OATP2 gene in Malay neonates with 
and without neonatal hyperbilirubinaemia.  
1.3.2 Specific objectives  
i. To screen for the selected genetic variations of the OATP2 gene using 
HRM analysis 
ii. To determine the genotype and allele frequencies of selected genetic 
variations of the OATP2 gene and their association with neonatal 
hyperbilirubinaemia in Malay neonates 
iii. To determine the haplotype frequencies of selected genetic variations of 
the OATP2 gene and their association with neonatal hyperbilirubinaemia 
in Malay neonates 
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1.4 Characteristics of neonatal hyperbilirubinaemia  
“Hyperbilirubinaemia” can be defined as the presence of excessive serum 
bilirubin in the circulation and the ranges are different between one country to 
other country. For example, in USA, hyperbilirubinaemia is defined as the 
presence of serum bilirubin levels ≥ 222 micromole per litre (µmol/L),  in 
Australia ≥ 154 µmol/L, in India ≥ 140 µmol/L and in Hong Kong and Singapore 
≥ 255 µmol/L (Lee et al., 1970; Palmer and Drew, 1983; Menon and Mohapatra, 
1987; Ho et al., 1988; Maisels, 1999).  
Up to 60% of full term neonates and 80% of premature neonates will 
develop neonatal hyperbilirubinaemia during their first day of life and usually 
will resolve after 7
 – 8 days (Kliegman and Behrman, 1992; A.A.o.P., 1994). 
During their hospitalization, the maximum limit of serum bilirubin levels will 
reach even though there were no other diseases detected. This level is also higher 
as compared with adults (≥ 5 – 17 µmol/L) and it is considered as abnormal (Ho, 
1992).  
Visible neonatal hyperbilirubinaemia indicated that there is presence of 
bilirubin outside the circulation such as in the skin and other lipid fat content 
tissues. During the early onset of neonatal hyperbilirubinaemia, the yellowness 
appears in the upper part of the body (on the face). Then, it will move down to 
the chest, abdomen and arms. Lastly, it will appear on the legs, which indicate 
that neonatal hyperbilirubinaemia is getting severe. This yellowness movement is 
called as the rostral and caudal pattern (Thaler and Gellis, 1968; Kramer, 1969; 
Knudsen, 1990).   
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The accumulation of bilirubin is dependent on its production and 
excretion. If the degree of mismatch between bilirubin production and its 
removal is moving toward accumulation and load, this will cause the rise of 
serum bilirubin levels in the circulation and neonatal hyperbilirubinaemia may 
occur (Kaplan et al., 2002). According to Cohen et al. (2010), problem in the 
bilirubin clearance is normally occur to liver disease patients or it may also result 
by the presence of genetic variations.  
The incidence of neonatal hyperbilirubinaemia is different between 
populations to populations. Most of the studies shown that Asian and American-
Indian population have highest prevalence of neonatal hyperbilirubinaemia as 
compared to Caucasian population (Robinson and Lee, 1991; Akaba et al., 1999; 
Dennery et al., 2001; A.A.o.P., 2004; Halamek and Stevenson, 2010). In 
addition, neonatal hyperbilirubinaemia in Caucasian generally less severe and 
occur in shorter duration (Robinson and Lee, 1991).  
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1.5 Classification of neonatal hyperbilirubinaemia 
1.5.1 Unconjugated hyperbilirubinaemia versus conjugated hyperbilirubinaemia 
Hyperbilirubinaemia can be classified based on the form of bilirubin 
that caused it; unconjugated and conjugated hyperbilirubinaemia (Figure 1.1). 
Unconjugated hyperbilirubinaemia is caused by the overproduction of 
bilirubin due to excessive haemolysis, defects in hepatic uptake or 
conjugation of bilirubin. A defect in the hepatic uptake and conjugation of 
bilirubin is related to the reduction of enzyme activities that are responsible to 
transport the bilirubin from circulation to the liver and to transform the 
bilirubin into its conjugated form. In addition, the neonates’ skin with 
unconjugated hyperbilirubinaemia will tend to appear bright yellow or 
sometimes orange. 
In contrast, conjugated hyperbilirubinaemia is related to bile secretion 
problems. After the bilirubin was conjugated, it will be excreted into bile to 
be removed from the body. However, this process is disturbed if there is 
deficient activity of protein that plays a role to transport conjugated bilirubin 
to the bile. As compared to unconjugated bilirubin, conjugated bilirubin is 
water soluble compound. Even though, water soluble bilirubin do not cause 
neurotoxicity, however elevated of its concentration in the circulation may 
potentially lead to serious disorder (Kliegman and Behrman, 1992). 
Neonates’ skin with conjugated hyperbilirubinaemia is tends to be greenish or 
muddy yellow (Kliegman and Behrman, 1992).  
Table 1.1 showed the causes of unconjugated and conjugated 
hyperbilirubinaemia.  
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1.5.2 Physiological hyperbilirubinaemia versus pathological hyperbilirubinaemia 
Unconjugated hyperbilirubinaemia can be further classified into 
physiological and pathological hyperbilirubinaemia (Figure 1.1). 
Physiological hyperbilirubinaemia also called as normal hyperbilirubinaemia. 
It is the event that occurs more common in premature neonates as compared 
to full term neonates. It is benign, normally appear within 3 – 4 days of life, 
disappear after 8 – 10 days of age (Kliegman and Behrman, 1992) and the 
peak of serum bilirubin levels were not exceed 290 µmol/L (Dennery et al., 
2001). In addition, neonates with physiological hyperbilirubinaemia usually 
required no treatment (Robinson and Lee, 1991; Cashore, 1999). 
However, pathological hyperbilirubinaemia may appear earlier, in less 
than 24 hours of life and occur in longer duration about more than 14 days. 
The peak of serum bilirubin levels was also higher (>290 µmol/L) within 24 
hours of life (Dennery et al., 2001; Porter and Dennis, 2002). According to 
Halamek and Stevenson (2010), if the serum bilirubin levels is exceeded 290 
µmol/L, it is not considered as physiological hyperbilirubinaemia and usually 
the causes of pathological hyperbilirubinaemia were identified in such 
neonates. 
Table 1.2 showed the causing factors of the physiological and 
pathological hyperbilirubinaemia.  
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Figure 1.1: Classification of neonatal hyperbilirubinaemia  
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Table 1.1: Causes of unconjugated and conjugated hyperbilirubinaemia (adapted 
from Kliegman and Behrman (1992) and Robinson and Lee (1991)) 
Unconjugated hyperbilirubinaemia  Conjugated hyperbilirubinaemia  
 Haemolysis factors (e.g.: blood 
group and Rh incompatibilities) 
 Structural and metabolic 
abnormalities of red blood cells 
(e.g.: G6PD deficiency and 
hereditary spherocytosis) 
 Genetic defect (reduce in enzyme 
activity)  
 Shorten of red blood cells life span 
 Urinary tract infection  
 Infant of diabetic mother 
 Cephalohaematoma, bruising  and 
haemorrhage  
 Breast milk  
 Prematurity  
 Intrauterine infection (e.g.: rubella, 
cytomegalovirus infection, 
toxoplasmosis and herpes simplex 
infection) 
 Viral and bacterial infection (e.g.: 
sepsis and neonatal hepatitis) 
 Metabolic disorder (e.g.: α-antitrypsin 
deficiency and galactosemia) 
 Carcinoma of the head of the pancreas 
 Biliary obstruction  
 Congenital biliary atresia 
 Stone in the bile duct  
 Pancreatic pseudocyst 
 Hepatocellular carcinoma 
 Post-asphyxia 
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Table 1.2: Causes of physiological and pathological hyperbilirubinaemia  
(adapted from Robinson and Lee, 1991; Dennery et al., 2001; Gartner, 2001) 
 
Physiological hyperbilirubinaemia Pathological hyperbilirubinaemia 
 Shorten of red blood cells life span  
 Immaturity of hepatic uptake and 
conjugation process (low enzyme 
activities) 
 Increase enterohepatic circulation 
 Prematurity  
 
 Haemolysis factors 
 Structural and metabolic 
abnormalities  
 Urinary tract infection   
 Bacterial infection (e.g: sepsis) 
 Cephalohaematoma  
 Bruising  
 Haemorrhage 
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1.6 Bilirubin production in neonates 
Bilirubin is a yellow pigments that is produced in the liver. The 
production of bilirubin started when neonates are still in the womb and can be 
detected during 12 weeks of gestation in normal amniotic fluid. However, the 
levels of serum bilirubin will decreased at 36 – 37 weeks due to activation of 
uridine diphosphate glucuronosyltransferase (UDPGT) enzyme (Maisels, 1999).  
Neonates have 2 – 3 times higher bilirubin metabolism and production 
rate as compared to children and adult, about 6 – 8 milligram per kilogram per 
day (mg/kg/day). High production of bilirubin is caused by several factors such 
as shorten of red blood cells life span, increase amount of haematocrit, increase 
of red blood cells volume and lack of hepatic function for conjugation and 
clearance of bilirubin (Kaplan et al., 2002; Porter and Dennis, 2002; Moerschel et 
al., 2008).  
Bilirubin is a waste product of heme metabolism. Heme can be found in 
red blood cells and the other oxidative compound such as hepatic mitochondrial, 
cytochrome P450 isoenzymes, catalase and peroxides (Tukey and Strassburg, 
2000; Volpe, 2008). However, about 75% of the bilirubin is from the red blood 
cells (Robinson and Lee, 1991). In bilirubin metabolism pathway, it involves 
several steps including production, transportation, hepatic uptake, conjugation, 
excretion and enterohepatic circulation (Volpe, 2008).  
First, when the red blood cells are broken down, the heme part will be 
converted into the biliverdin (green pigment) and carbon monoxide by heme 
oxygenase. Then, biliverdin is reduced to bilirubin (yellow pigment) by 
biliverdin reductase in the presence of nicotinamide adenine dinucleotide 
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phosphate (NADPH). In this stage, bilirubin is in unconjugated and unbound 
form. After bilirubin reaches the blood plasma, it is tightly bound to albumin to 
form bilirubin-albumin complex and is transported to the liver. According to 
Dennery et al. (2001), 1 gram (g) of albumin can bind to the 8.2 milligram (mg) 
of bilirubin. The unconjugated bilirubin that bound to the albumin is also called 
as indirect bilirubin.  
After bilirubin reaches the liver, uptake process is taking place in the 
sinusoidal cell membrane of hepatocytes. A variety of organic anion transporting 
polypeptide play its role in the uptake of unconjugated bilirubin from the blood to 
the liver and these transporters are very selective for their substrates. However, 
the most significant transporter for bilirubin is an organic anion transporting 
polypeptide 2 (OATP2) protein. When unconjugated bilirubin enters the 
hepatocytes, it will bind to the group of cytosolic proteins which is also known as 
glutathione S-transferases or ligandins to the site where the bilirubin conjugation 
takes place. 
The conjugation process is conducted by UDPGT enzyme in the liver. It 
is a process of esterification of bilirubin’s propionic acid with glucuronic acid. 
This process allows the unconjugated bilirubin to become conjugated bilirubin 
(direct bilirubin), a water soluble compound. Eighty percent (80%) of bilirubin is 
in the diglucuronide form and another 20% is in the monoglucuronide form 
(McCandless, 2011). After conjugation takes place, the conjugated bilirubin will 
be diffused through the cytosol to be excreted to the bile. This step is mediated 
by the adenosine triphosphate (ATP) dependent transport protein, multidrug 
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resistance-associated protein 2 (MRP2) (Büchler et al., 1996). Figure 1.2 shows 
how the bilirubin is taken up to the liver until it was excreted to the bile.  
From the bile, the bilirubin is excreted to the small intestine. Bilirubin in 
the small intestine and colon is reduced to urobilinogen (colourless) by bacterial 
dehydrogenase and later will be reduced again to urobilin (orange-yellow). 
Urobilin is excreted to the feces and giving it a light tan colour. However, small 
amounts of urobilinogen will be reabsorbed by the small intestine and colon to 
the liver and will be excreted in the urine. Higher concentration of the 
urobilinogen in the urine gives it dark yellow brown colour.  Overall process of 
bilirubin metabolism pathway is shown in Figure 1.3.  
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Figure 1.2: Bilirubin transportation, uptake, conjugation and excretion in the 
hepatocytes (adapted from Jansen and Bittar, 2004) 
 
Note: B = Bilirubin; ALB = Albumin; LIG = Ligandin; BG2 = Bilirubin diglucuronide; BA = Bile 
acid; OATP2 = Organic anion transporting polypeptide 2; UGT1A1 = Uridine diphosphate 
glucuronosyltransferase 1A1; MRP2 = Multidrug resistance-associated protein 2; BSEP = Bile Salt 
Export Pump 
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Figure 1.3: Bilirubin metabolism pathway  
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1.7 Effects of neonatal hyperbilirubinaemia 
In the early stage, neonatal hyperbilirubinaemia normally present in a 
benign state and later on become more serious if it is unmonitored or untreated 
(A.A.o.P., 2004). Free bilirubin (unbound to albumin) is able to enter the brain 
tissue through several ways, including blood brain barrier or the choroid plexus 
and can cause kernicterus (Kaplan and Hammerman, 2005). However, the most 
significant and important is through the blood brain barrier (Volpe, 2008). The 
presence of bilirubin in the central nervous system may result in brain 
encephalopathy (acute bilirubin intoxication), kernicterus (the most severe form 
of brain damage) and sometimes leads to death (Bhutani and Johnson, 2003; 
Morioka et al., 2013). The term “kernicterus” was described as a presence of 
yellow staining in basal ganglia and this term was first used by Schmorl in early 
1904 (Figure 1.4).   
According to Ives (2011), these effects are more likely to occur in 
premature neonates as compared to the full term neonates. Even though full term 
neonates have high serum bilirubin levels than premature neonates, however, the 
risk of kernicterus is low (Kliegman and Behrman, 1992). This situation is due to 
the immaturity of central nervous system and lower albumin level in premature 
neonates.  
Brain encephalopathy usually occurs within the first weeks of life and it 
shows some clinical manifestation such as lethargy, hypertonia, irritability, fever, 
apnea and seizure. However, kernicterus can cause chronic and permanent 
clinical sequelae of bilirubin toxicity such as athetoid cerebral palsy, facial 
grimacing, dental-enamel dysplasia, paralysis and hearing loss (Robinson and 
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Lee, 1991; A.A.o.P., 2004).  Other than neurotoxicity effect, increase of bilirubin 
in the body may cause cellular injury. Previous work indicated that high levels of 
bilirubin may cause disturbance in mitochondrial enzyme activity, oxidative 
phosphorylation, amino acid and protein metabolism, deoxyribonucleic acid 
(DNA) synthesis and synaptic transmission (Amato et al., 1994; Chuniaud et al., 
1996).  
Neonatal hyperbilirubinaemia is the common reason for hospital 
admission of neonates and it is the second cause of death with percentage of 
14.1% (Owa and Osinaike, 1998). English et al. (2003) also found neonatal 
hyperbilirubinaemia is the major cause of death for the neonates with a mortality 
rate of 24%. In addition, Ugwu et al. (2006) had reported that the tendency for 
the neonates to die due to neonatal hyperbilirubinaemia is same as birth asphyxia 
and this is higher than sepsis.  
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Figure 1.4: Yellow discolouration of basal ganglia (modified from Hansen (2000)) 
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1.8 Managements and treatments for neonatal hyperbilirubinaemia 
1.8.1 Phototherapy 
In most hospitals, phototherapy is a standard treatment for neonatal 
hyperbilirubinaemia. It is involves exposure of the blue light with a 
wavelength of approximately 450 nm to the neonates’ body (preferably 
naked) with eye covered. Bilirubin will absorb the blue light and will 
transform to the lumirubin which will be excreted more easily by the liver 
and kidney than other isomer (McDonagh and Lightner, 1985; Ennever et al., 
1987). However, diarrhea, intestinal hypermotility and insensible water loss 
are the complications of phototherapy (Maisels and McDonagh, 2008).  
1.8.2 Exchange transfusion  
Exchange transfusion is a procedure involves replacement of patient’s 
blood with an equal amount of fresh blood. Exchange transfusion is the best 
method of choice if the neonates suffer from hemolytic anaemia or when the 
phototherapy treatment is fail. Other than that, it is also suitable for the 
neonates who are facing rapid increasing of serum bilirubin levels probably 
340 µmol/L within 48 hours or the neonates with serum bilirubin levels of 
430 µmol/L with 48 – 72 hours of life (A.A.o.P., 1994; Jansen and Bittar, 
2004). In 1950s, exchange transfusion was the primary treatment for neonatal 
hyperbilirubinaemia (Watchko, 2005). Similar to phototherapy treatment, 
exchange transfusion can cause some complication such as vasospasm, 
thrombocytopenia, electrolyte imbalance, infection and even death.  
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1.8.3 Pharmacological therapies 
Intravenous immunoglobulin (IVIG), phenobarbital and 
ursodeoxycholic acid was used in order to reduce the bilirubin concentration, 
improve bile flow and enhance enzyme activity that involves in the 
conjugation and excretion of bilirubin (Stern et al., 1970; Dennery, 2002). As 
compared to all medicine, phenobarbital is the most common drug used to 
treat neonatal hyperbilirubinaemia. However, phenobarbital may alter the 
oxidation properties of bilirubin and increase the risk of occurrence of 
kernicterus (Hansen and Tommarello, 1998; Kaplan and Hammerman, 2002).  
 
 
 
 
 
 
 
 
 
 
 
